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Background and Purpose Nonbacterial thrombotic endocarditis (NBTE) is a cause of stroke in 
cancer. However, clinical characteristics and outcomes in stroke patients with cancer-associated 
NBTE are not well known.
Methods We included consecutive patients with stroke and active cancer over a 9-year period who 
underwent echocardiography. We retrospectively compared clinical characteristics and presence of 
metastasis between patients with NBTE, those with cryptogenic etiologies, and those with 
determined etiologies. We also investigated mortality and stroke events during the 6-month 
follow-up. 
Results Among the 245 patients, 20 had NBTE, 96 had cryptogenic etiologies, and 129 had 
determined etiologies. Metastasis was seen in all 20 patients (100%) with NBTE, 69.8% in patients 
with cryptogenic etiology, and 48.8% in patients with or determined etiology. During the 6-month 
follow-up, 127 patients (51.8%) developed stroke and/or died (death in 110 [44.9%] and stroke 
events in 55 [22.4%]). Patients with NBTE showed significantly higher mortality (80%) and stroke 
occurrence (50%) than those with cryptogenic etiologies (mortality 54.2%, stroke 25.0%, log-rank 
P=0.006) and determined etiologies (mortality 32.6%, stroke 16.3%, log-rank P<0.001). In a 
multivariate Cox proportional hazard analysis, the presence of NBTE was independently associated 
with composite outcomes of mortality and stroke events (hazard ratio, 1.941; 95% confidence 
interval, 1.052 to 3.690).
Conclusions NBTE should be suspected as a potential cause of stroke in patients with metastatic 
cancer. Patients with NBTE have a high risk of recurrent stroke and mortality. Future studies are 
necessary to determine strategies to reduce stroke recurrence in patients with NBTE.
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Introduction
Cancer may be associated with stroke. In a large cohort study, 
the 6-month cumulative incidence of ischemic stroke was sig-
nificantly higher in patients with cancer than in matched con-
trols (3.0% vs. 1.62%).1 Nonbacterial thrombotic endocarditis 
(NBTE) is characterized by noninfectious vegetation on the 
cardiac valves.2 NBTE is a cause of stroke and most frequently 
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develops in patients with systemic cancer.3,4 
Most information on NBTE in stroke is derived from case re-
ports or post-mortem studies because of its rarity.5-8 Although 
patients with acute stroke and active cancer are known to have 
a substantial short-term risk of recurrent stroke,9 the outcomes 
of stroke patients with cancer-associated NBTE are not well 
known. In addition, the pathomechanism of NBTE is unknown. 
However, pathological studies have shown that the vegetation 
and thrombi retrieved from stroke patients with NBTE have very 
high platelet fractions.10,11 Further, cancer is known to activate 
platelets, which play an important role in metastasis.12 These 
findings suggest a potential association between NBTE and me-
tastasis. Previous case reports and post-mortem studies have 
shown frequent occurrences of metastasis in patients with 
NBTE. However, information on the presence of metastasis is 
insufficient in many cases.13-16 Therefore, the association be-
tween NBTE and metastasis remains uncertain.
We hypothesized that development of NBTE has a relation-
ship with metastasis. In this study, we investigated association 
between NBTE and metastasis, and the mortality and occur-
rence of stroke events for 6 months following an initial stroke 
in patients with cancer-associated NBTE. 
Methods
Study population
This retrospective study used a hospital-based prospective co-
hort of consecutively enrolled patients with ischemic stroke 
within 7 days of symptoms onset. Routine evaluations per-
formed were as follows: standard blood tests including D-di-
mer; brain magnetic resonance imaging (MRI) and/or comput-
ed tomography (CT) and cerebral angiography (magnetic reso-
nance angiography, CT angiography, or conventional angiogra-
phy); Holter monitoring or continuous electrocardiography 
monitoring during admission in the stroke unit; and trans-
esophageal echocardiography (TEE) and/or transthoracic echo-
cardiography (TTE). TEE was not performed in patients with de-
creased consciousness, aphasia, impending brain herniation, 
poor systemic conditions, severe swallowing difficulty, tracheal 
intubation, or when informed consent could not be obtained.17 
The study hospital is a tertiary university hospital with a 
dedicated cancer center where patients with cancer routinely 
undergo extensive evaluations for the presence of metastasis. 
When cancer or NBTE is diagnosed during admission, patients 
are referred to oncologists for further evaluation and treat-
ment.
This study included consecutive patients with active cancer 
who were registered between January 2010 and December 2018 
and who underwent echocardiography. Active cancer was de-
fined as cancer that was diagnosed within 6 months, required 
chemotherapy or surgical treatment within 6 months, or was re-
current, metastatic, or inoperable.18 Patients with brain malig-
nancy or hematologic malignancy were excluded. The cohort and 
this study were approved by the Institutional Review Board of 
the Yonsei University Health System. The need for an informed 
consent was waived due to the retrospective nature of the study.
Study group
Because the study participants had active cancer, patients were 
categorized into those with NBTE, those with cryptogenic eti-
ology, and those with determined etiology.11 NBTE was deter-
mined based on formal reports by cardiologists who diagnosed 
vegetation based on echocardiographic examinations. Five pa-
tients with NBTE and co-existing atrial fibrillation were classi-
fied into the NBTE group. Twenty-one patients with a patent 
foramen ovale without venous thrombosis and other determin-
able etiologies were classified into cryptogenic etiology group.
Outcome assessments
All patients were regularly followed up after discharge by neu-
rologists and clinical research assistants in the outpatient clinic 
using face-to-face interviews or by a telephonic interview us-
ing a structured questionnaire.19 We reviewed the medical re-
cords to obtain information on mortality and cause of death. 
The cause of death was categorized as stroke-related, cancer-
related, or others/unknown.20 Information on the occurrence of 
any new stroke events (cerebral infarction or intracerebral 
hemorrhage [ICH]) after the initial cerebral infarction was also 
obtained from medical records. The diagnosis of stroke was 
based on brain MRI and/or CT results.
Statistical analysis
Variables were expressed as mean±standard deviation, median 
(interquartile range), or number (percentage), as appropriate. 
Baseline characteristics among the groups were compared using 
one-way analysis of variance or the Kruskal-Wallis test for con-
tinuous variables and the chi-square test or Fisher’s exact test 
for categorical variables. Post hoc analysis was performed using 
Bonferroni’s correction or Dunn’s test. Kaplan-Meier estimates 
and log-rank tests were performed (adjusted by Bonferroni’s cor-
rection) for mortality, occurrence of stroke, and composite out-
comes of mortality and stroke. To determine whether the pres-
ence of NBTE was associated with composite events of mortality 
and stroke, we performed multivariate Cox proportional hazard 
regression analyses. As all patients with NBTE had metastasis 
and 90% of patients with NBTE had multiple territory infarc-
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tions, we constructed two different multivariate regression mod-
els to avoid multicollinearity. Model 1 included the presence of 
NBTE and Model 2 included metastasis and multiple territory in-
farctions. All statistical analyses were performed using R statisti-
cal software version 3.5.1 (http://www.R-project.org). A P<0.05 
was considered statistically significant.
Results
During the 9-year study period, 289 patients with acute isch-
emic stroke and active cancer were registered to the cohort. Of 
those, 245 patients (84.8%) underwent echocardiography and 
were included in this study (123 patients underwent both TEE 
and TTE, 25 patients underwent TEE only, and 97 patients un-
derwent TTE only). The mean age of the included patients was 
68.7±10.7 years, and 136 patients (55.5%) were men. Com-
pared to patients who underwent echocardiography, those who 
did not undergo echocardiography were younger, had fewer 
atrial fibrillation and higher National Institutes of Health 
Stroke Scale (NIHSS) scores. Cancer types were not different 
between patients who did or did not undergo echocardiogra-
phy (Supplementary Table 1).
Comparison between the groups
Of the 245 patients, 20 patients (8.2%) had NBTE, 96 (39.2%) 
had a cryptogenic etiology, and 129 (52.7%) had determined 
etiologies. In patients with determined etiologies, those with 
cardioembolism were 51, those with large artery atherosclero-
sis were 46, and those with two or more causes were 19 (Sup-
plementary Table 2). Of 150 patients (61.2%) with metastasis, 
NBTE was diagnosed in 20 patients (13.3%). Compared with 
patients with determined etiologies, those with NBTE were 
younger, had more frequent multiple vascular territory involve-
ment, lower platelet counts, lower fibrinogen levels, and higher 
D-dimer levels (Table 1).
Metastasis, cancer type, and NBTE
All 20 patients with NBTE had metastasis, and NBTE was not 
detected in patients without metastasis. The presence of me-
tastasis was significantly higher in patients with NBTE (100%) 
than in those with stroke with a cryptogenic etiology (69.8%; 
P=0.014 after Bonferroni’s correction) or those with a deter-
mined etiology (48.8%; P<0.001 after Bonferroni’s correction) 
(Table 1). The cancer type was not significantly different among 
the three groups (Table 1).
Six-month mortality and stroke events
All patients were followed up for 6 months after the initial 
stroke event. During the follow-up, 127 patients (51.8%) de-
veloped stroke events and/or died (110 [44.9%] died and 55 
[22.4%] patients experienced stroke events). The median sur-
vival of patients with NBTE was 44.5 days, and event-free sur-
vival of composite outcomes of mortality and stroke was 36 
days. During the 6-month follow-up, 90% (18/20) patients 
with NBTE died or developed stroke, while only 38.8% patients 
with a determined etiology died or developed stroke (50/129, 
P<0.001) (Table 2).
Compared to event-free patients, those with events (mortal-
ity or stroke) were younger and had lower body mass indices 
and higher initial NIHSS scores. They also had lower hemoglo-
bin levels, platelet counts, and fibrinogen levels, and higher 
white blood cell counts and D-dimer levels (Table 3). Metasta-
sis and multiple vascular territory involvements were more 
common in patients with mortality or stroke events. Cancer 
type was also different between patients with or without 
events (Table 3). 
In the Kaplan-Meier survival analysis, the 6-month mortality 
was different among the three groups (P<0.001). Patients with 
NBTE showed lower 6-month survival probability, lower stroke-
free probability, and lower event-free probability than those 
with cryptogenic or determined etiologies (Figure 1). Mortality, 
stroke events, and composite outcomes were more common in 
patients with a cryptogenic etiology than in those with a de-
termined etiology (Figure 1).
Causes of death
During the follow-up, more patients with NBTE died (16/20 
[80.0%]) compared to those with a cryptogenic etiology (52/96 
[54.2%]) and a determined etiology (32/129 [32.6%]) 
(P<0.001). Causes of death were cancer-related in 83 (75.5%), 
stroke-related in 21 (19.1%), and other/unknown in six (5.5%) 
patients. The cause of death did not significantly differ among 
the three groups (P=0.307) (Table 2). 
Stroke events
During the 6-month follow-up, stroke events occurred in 55/245 
(22.4%) of patients; 53 (21.6%) with ischemic stroke and two 
(0.8%) with ICH. Stroke was diagnosed using diffusion-weighted 
imaging in 49 patients (89.1%) and by CT in five patients (9.1%). 
The type of imaging was uncertain in one patient who was diag-
nosed at another hospital (1.8%). Stroke events occurred most 
frequently in patients with NBTE (10/20, 50%), followed by those 
with a cryptogenic etiology (24/96, 25.0%) and those with a de-
termined etiology (21/129, 16.3%) (Table 2). Mortality was more 
frequent in patients with stroke events than in those without 
(69.1% [38/55] vs. 37.9% [72/190], P<0.001).
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Table 1. Comparison of baseline characteristics according to stroke etiology
Characteristic NBTE (n=20) Cryptogenic etiology (n=96) Determined etiology (n=129) P
Demographics
Age (yr) 61.5±8.7 68.1±10.1 70.3±10.9 0.002*,†
Male sex 9 (45.0) 43 (44.8) 84 (65.1) 0.006‡
Risk factors
Hypertension 10 (50.0) 57 (59.4) 92 (71.3) 0.062
Diabetes mellitus 5 (25.0) 25 (26.0) 47 (36.4) 0.204
Dyslipidemia 5 (25.0) 13 (13.5) 28 (21.7) 0.228
Atrial fibrillation 5 (25.0) 0 (0) 46 (35.7) <0.001*,‡
Current smoker 1 (5.0) 12 (12.5) 17 (13.2) 0.581
Patent foramen ovale 3 (15.0) 21 (21.9) 26 (20.2) 0.782
Body mass index (kg/m2) 22.3±2.9 22.8±3.5 22.5±3.6 0.676
Medications prior to admission
Antiplatelets 3 (15.0) 19 (19.8) 39 (30.2) 0.129
Anticoagulants 3 (15.0) 4 (4.2) 15 (11.6) 0.066
Statin 7 (35.0) 18 (18.8) 37 (28.7) 0.138
Medications mainly used after admission 0.048‡
Antiplatelets 6 (30.0) 56 (58.3) 73 (56.6)
Anticoagulants 12 (60.0) 31 (32.3) 49 (38.0)
Both antiplatelets and anticoagulants 1 (5.0) 2 (2.1) 5 (3.9)
No medication 1 (5.0) 7 (7.3) 2 (1.6)
Initial NIHSS score 7 (3–12) 5 (2–10) 5 (1–12) 0.547
Reperfusion therapy 6 (30.0) 12 (12.6) 28 (21.7) 0.095
Multiple territory involvement 18 (90.0) 62 (64.6) 47 (36.4) <0.001†,‡
Laboratory findings
Hemoglobin (g/dL) 11.2±1.6 10.8±2.0 11.7±2.8 0.036‡
White blood cells (×109/L) 10.4±5.1 7.8±3.9 8.1±4.2 0.041*
Platelets (×109/L) 133±82 201±113 237±118 <0.001*,†
D-dimer (mg/L) 7.4±6.5 4.8±9.0 1.9±2.8 <0.001†,‡
Fibrinogen (g/L) 2.6±1.6 3.3±1.4 3.5±1.3 0.013†
Metastatic cancer 20 (100.0) 67 (69.8) 63 (48.8) <0.001*,†,‡
Cancer type 0.118
Colorectal 2 (10.0) 11 (11.5) 19 (14.7)
Gastric/esophageal 3 (15.0) 14 (14.6) 27 (20.9)
Hepatobiliary 6 (30.0) 20 (20.8) 12 (9.3)
Pancreas 4 (20.0) 9 (9.4) 9 (7.0)
Lung 1 (5.0) 21 (21.9) 24 (18.6)
Bladder/urinary tract 2 (10.0) 3 (3.1) 6 (4.7)
Female genital organ 1 (5.0) 5 (5.2) 6 (4.7)
Others 1 (5.0) 13 (13.5) 26 (20.2)
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
NBTE, nonbacterial thrombotic endocarditis; NIHSS, National Institutes of Health Stroke Scale.
*NBTE vs. Cryptogenic, P<0.05; †NBTE vs. Determined, P<0.05; ‡Cryptogenic vs. Determined, P<0.05.
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Factors associated with mortality and stroke 
events
In the multivariate Cox proportional hazard analysis, female 
sex and a lower body mass index were associated with com-
posite outcomes of mortality and stroke both in Model 1 and 
Model 2. The composite outcomes were independently associ-
ated with the presence of NBTE (hazard ratio [HR], 1.941; 95% 
confidence interval [CI], 1.052 to 3.690) (Table 4, Model 1). The 
presence of metastasis (HR, 2.870; 95% CI, 1.648 to 4.996) and 
the involvement of multiple vascular territories (HR, 2.524; 
95% CI, 1.570 to 4.058) were also independently associated 
with the composite outcomes (Table 4, Model 2). 
Discussion
In this study, NBTE was diagnosed in approximately one of 11 
stroke patients with active cancer. NBTE was also found exclu-
sively in patients with metastasis. In addition, stroke patients 
with NBTE had a very high risk of mortality and stroke events 
during a 6-month follow-up. 
The pathomechanism of NBTE remains unknown. Autopsy 
studies in patients with NBTE have shown that cardiac vegeta-
tion is mainly composed of platelets,21 and examinations of 
thrombi retrieved during mechanical thrombectomy in stroke 
patients with NBTE have indicated very high platelet and low 
erythrocyte fractions.11,22 These studies suggest that platelet-
mediated mechanisms play a key role in the development of 
cancer-associated NBTE. The role of platelets in cancer has 
been extensively studied; platelets play a crucial role in tumor 
growth and metastasis.23
Our study demonstrated that NBTE occurred exclusively in 
patients with metastasis. Platelets can contribute to tumor in-
vasion and metastasis via several mechanisms. Platelets are es-
sential for the survival of circulating tumor cells,24 and these 
cells rapidly associate with platelets via their receptors and in-
duce tumor cell-induced platelet aggregation (TCIPA).25 This 
TCIPA is critical for tumor cell survival as platelets form a phys-
ical shield around tumor cells, protecting them from recogni-
tion and lysis by natural killer cells and shear-induced dam-
age.26,27 These findings suggest that the association of tumor 
cells with platelets during metastasis may somehow contribute 
to the development of platelet-rich vegetation in NBTE. 
Stroke patients with active cancer have a substantial risk of 
recurrent stroke. In a retrospective study, ischemic stroke re-
curred in 16% patients within 6 months of the initial stroke.15 
In the present study cohort, ischemic stroke recurred in 21.6% 
patients and ICH developed in 0.8% patients. Particularly, 50% 
patients with NBTE developed stroke within 6 months, signifi-
cantly higher than those without NBTE. Ninety percent of pa-
tients with NBTE had lesions involving multiple vascular terri-
tories, which suggests multiple embolization from the heart. 
Patients with NBTE may be prone to a high risk of multiple 
thromboembolism because the platelet-rich vegetation 
(thrombus) is attached to the fast-moving cardiac valves. 
This study showed that mortality differed significantly 
among the three etiology categories of stroke patients with 
active cancer. During the 6 months of follow-up, 80% patients 
with NBTE died. However, less than one-third of the patients 
with a determined etiology died. Patients with a cryptogenic 
etiology had an intermediate risk of 6-month mortality. The 
high mortality in patients with NBTE may be associated with 
metastasis since all patients with NBTE had it. In our previous 
study, 67.1% stroke patients with metastatic cancer died with-
in 6 months,20 but the 6-month mortality in patients with 
Table 2. Causes of death and type of stroke event according to stroke etiology
Variable NBTE (n=20) Cryptogenic etiology (n=96) Determined etiology (n=129) P
Composite outcomes of mortality and stroke 18 (90) 59 (61.5) 50 (38.8) <0.001*,†,‡
Mortality 16 (80) 52 (54.2) 32 (32.6) <0.001†,‡
Causes of death 0.307
Cancer-related 13 (81.2) 43 (82.7) 27 (64.3)
Stroke-related 2 (12.5) 7 (13.5) 12 (28.6)
Other/unknown cause 1 (6.3) 2 (3.8) 3 (7.1)
Any stroke events 10 (50) 24 (25.0) 21 (16.3) <0.003†
Stroke type
Cerebral infarction 10 (100) 23 (95.8) 20 (95.2)
Intracerebral hemorrhage  0 (0) 1 (4.2) 1 (4.8)
Values are presented as number (%).
NBTE, nonbacterial thrombotic endocarditis.
*NBTE vs. Cryptogenic, P<0.05; †NBTE vs. Determined, P<0.05; ‡Cryptogenic vs. Determined, P<0.05.
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NBTE was even higher. In the present study, mortality was also 
higher in patients who developed recurrent stroke; therefore, 
frequent stroke reoccurrence in patients with NBTE might also 
increase the risk of death.
In this study, patients with NBTE had higher D-dimer levels 
and more frequent multiple vascular territory involvement than 
those of patients with stroke of a determined etiology. These 
are known characteristics of cancer-related stroke.3 Our find-
ings suggest that some features of cancer-related stroke may 
be associated with NBTE.28,29 Patients with a cryptogenic etiol-
ogy had intermediate characteristics between those with NBTE 
and those with a determined etiology. Although NBTE is often 
not diagnosed despite TEE being performed,30 NBTE has been 
suggested as the likely cause of cryptogenic stroke in many pa-
tients with cancer.29 Therefore, undiagnosed NBTE may have 
been present in some patients with a cryptogenic etiology. 
This study has several limitations. First, although patients 
were enrolled prospectively, analysis for this study was per-









Age (yr) 68.4±9.9 69.0±11.4 0.664
Male sex 80 (67.8) 56 (44.1) <0.001
Risk factors
Hypertension 79 (66.9) 80 (63.0) 0.607
Diabetes mellitus 39 (33.1) 38 (29.9) 0.697
Dyslipidemia 27 (22.9) 19 (15.0) 0.155
Atrial fibrillation 26 (22.0) 25 (19.7) 0.768
Current smoker 20 (16.9) 10 (7.9) 0.049
Body mass index (kg/m2) 23.2±3.2 22.0±3.8 0.010
Metastatic cancer 42 (35.6) 108 (85.0) <0.001
Cancer type 0.020
Colorectal 19 (16.1) 13 (10.2)
Gastric/esophageal 22 (18.6) 22 (17.3)
Hepatobiliary 13 (11.0) 25 (19.7)
Pancreas 5 (4.2) 17 (13.4)
Lung 21 (17.8) 25 (19.7)
Bladder/urinary tract 8 (6.8) 3 (2.4)
Female genital organ 5 (4.2) 7 (5.5)
Others 25 (21.2) 15 (11.8)
Initial NIHSS score 3 (1–10) 6 (2–11.5) 0.007
Reperfusion therapy 25 (21.2) 21 (16.7) 0.460
Multiple vascular territory involvement 36 (30.5) 91 (71.7) <0.001
Stroke etiology <0.001
NBTE 2 (10.0) 18 (90.0)
Cryptogenic 37 (38.5) 59 (61.5)
Determined 79 (61.2) 50 (38.8)
Laboratory findings
Hemoglobin (g/dL) 11.6±2.1 11.0±2.7 0.033
White blood cells (×109/L) 7.5±3.7 8.9±4.5 0.008
Platelets (×109/L) 243±112 188±116 <0.001
D-dimer (mg/L) 1.1±1.5 5.7±8.3 <0.001
Fibrinogen (g/L) 3.6±1.2 3.2±1.5 0.021
Values are presented as mean±standard deviation, number (%), or median 
(interquartile range).
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Figure 1. Kaplan-Meyer analysis of (A) mortality, (B) stroke events, and (C) 
composite outcomes of mortality and stroke events during the 6-month 
follow-up. Bonferroni’s correction was performed for intergroup compari-
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formed retrospectively at a single center. In addition, as the 
study hospital has a dedicated cancer center, the frequency of 
cancer, particularly that of advanced cancer or metastasis, 
might be higher than that in other more general hospitals. 
Second, although most patients (85%) with active cancer un-
derwent echocardiography, TEE (the gold standard for diagnosis 




Model 1 Model 2
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Demographics
Age (yr) 0.999 (0.982–1.017) 0.931 1.015 (0.996–1.034) 0.137 1.011 (0.992–1.030) 0.269
Male sex 0.471 (0.331–0.669) <0.001 0.540 (0.347–0.851) 0.007 0.520 (0.333–0.810) 0.004
Risk factors
Hypertension 0.841 (0.587–1.206) 0.347
Diabetes mellitus 0.877 (0.600–1.282) 0.498
Dyslipidemia 0.665 (0.408–1.083) 0.101 0.878 (0.519–1.463) 0.625 0.948 (0.561–1.601) 0.840
Atrial fibrillation 0.902 (0.582–1.396) 0.643
Current smoker 0.500 (0.262–0.955) 0.036 0.938 (0.429–1.807) 0.862 0.856 (0.418–1.753) 0.670
Body mass index (kg/m2) 0.927 (0.878–0.979) 0.007 0.926 (0.869–0.980) 0.012 0.929 (0.875–0.986) 0.015
Stroke etiology
Determined Reference Reference
Cryptogenic 1.976 (1.355–2.882) <0.001 1.447 (0.938–2.218) 0.090
NBTE 4.099 (2.371–7.086) <0.001 1.941 (1.052–3.690) 0.038
Medications mainly used after admission*
Antiplatelets Reference Reference Reference
Anticoagulants 1.810 (1.277–2.567) 0.001 1.353 (0.915–1.999) 0.130 0.958 (0.644–1.427) 0.834
Presence of metastasis 5.332 (3.264–8.708) <0.001 2.870 (1.648–4.996) <0.001
Cancer type
Colorectal 1.113 (0.530–2.339) 0.778 0.694 (0.326–1.565) 0.362 0.796 (0.360–1.761) 0.573
Gastric/esophageal 1.521 (0.789–2.932) 0.210 1.415 (0.675–2.839) 0.342 1.399 (0.682–2.868) 0.359
Hepatobiliary 2.196 (1.157–4.167) 0.016 1.522 (0.745–2.997) 0.236 1.312 (0.649–2.656) 0.450
Pancreas 2.812 (1.402–5.638) 0.004 1.093 (0.513–2.460) 0.826 0.767 (0.339–1.734) 0.523
Lung 1.628 (0.858–3.087) 0.136 1.330 (0.670–2.568) 0.404 1.084 (0.550–2.133) 0.816
Bladder/urinary tract 0.648 (0.188–2.238) 0.493 0.686 (0.201–2.788) 0.576 1.120 (0.293–4.280) 0.869
Female genital organ 2.059 (0.839–5.052) 0.115 1.180 (0.477–3.289) 0.738 1.115 (0.424–2.936) 0.825
Others Reference Reference Reference
Initial NIHSS score 1.031 (1.004–1.058) 0.024 1.023 (0.994–1.056) 0.140 1.028 (0.998–1.060) 0.071
Reperfusion therapy 0.808 (0.506–1.291) 0.372
Multiple vascular territory involvement 3.662 (2.482–5.403) <0.001 2.524 (1.570–4.058) <0.001
Laboratory findings
Hemoglobin (g/dL) 0.918 (0.847–0.994) 0.034 0.960 (0.864–1.046) 0.415 1.007 (0.920–1.102) 0.879
White blood cells (×109/L) 1.061 (1.020–1.104) 0.004 1.095 (1.040–1.145) <0.001 1.094 (1.040–1.151) 0.001
Platelets (×109/L) 0.996 (0.994–0.998) <0.001 0.997 (0.995–0.999) 0.003 0.997 (0.996–0.999) 0.006
D-dimer (mg/L) 1.078 (1.061–1.095) <0.001 1.053 (1.028–1.078) <0.001 1.033 (1.006–1.062) 0.018
Fibrinogen (g/L) 0.998 (0.996–0.999) 0.002 0.999 (0.998–1.001) 0.480 0.999 (0.997–1.001) 0.174
HR, hazard ratio; CI, confidence interval; NBTE, nonbacterial thrombotic endocarditis; NIHSS, National Institutes of Health Stroke Scale.
*Excluded eight patients with both antiplatelet and anticoagulant, 10 patients without antithrombotics.
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of vegetation30,31) was used in only 60.4%. Although TEE is one 
of the routine evaluations in our protocol, it was impractical to 
perform TEE in all patients (it is semi-invasive and requires pa-
tient cooperation and informed consent). Vegetation is often 
invisible on TTE, and even when using TEE, a small vegetation 
may not be detected. Therefore, the presence of NBTE in this 
study might have been underestimated. Third, the antithrom-
botic treatment for stroke prevention in our study population 
was not controlled. Therefore, the influence of preventive 
treatment on stroke recurrence is unknown. Finally, our expla-
nation on the role of platelets in metastasis and development 
of NBTE is speculative. 
Conclusions
NBTE should be suspected as a potential mechanism of stroke 
in patients with metastatic cancer, particularly in those with-
out determinable etiologies. We also showed that patients with 
NBTE have a very high short-term risk of recurrent stroke and 
mortality. In addition, mortality was higher in patients who de-
veloped recurrent stroke. In this regard, efforts are necessary to 
reduce the risk of stroke recurrence in these patients. Further 
studies are necessary to determine optimal preventive treat-
ment in stroke patients with cancer-associated NBTE. 
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Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2020.00619.
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Age (yr) 64.1±10.5 68.7±10.7 0.010
Male sex 25 (56.8) 136 (55.5) >0.999
Risk factors
Hypertension 25 (56.8) 159 (64.9) 0.392
Diabetes mellitus 14 (31.8) 77 (31.4) >0.999
Dyslipidemia 7 (15.9) 46 (18.8) 0.810
Atrial fibrillation 2 (4.6) 51 (20.8) 0.018
Current smoker 7 (15.9) 46 (18.8) 0.810
Body mass index (kg/m2) 21.8±3.2 22.6±3.5 0.162
Metastatic cancer 34 (77.3) 150 (61.2) 0.062
Cancer type 0.556
Colorectal 4 (9.1) 32 (13.1)
Gastric/esophageal 6 (13.6) 44 (18.0)
Hepatobiliary 4 (9.1) 38 (15.5)
Pancreas 8 (18.2) 22 (9.0)
Lung 11 (25.0) 46 (18.8)
Bladder/urinary tract 2 (4.5) 11 (4.5)
Female genital organ 1 (2.3) 12 (4.9)
Others 8 (18.2) 40 (16.3)
Initial NIHSS score 6.5 (3–15) 5 (2–11) 0.041
Reperfusion therapy 8 (18.2) 46 (18.9) >0.999
Multiple vascular territory involvement 20 (45.5) 127 (51.8) 0.538
Laboratory findings
Hemoglobin (g/dL) 11.1±1.8 11.3±2.4 0.557
White blood cells (×109/L) 9.1±5.0 8.2±4.2 0.285
Platelets (×109/L) 219±120 214±117 0.806
D-dimer (mg/L) 5.2±8.0 3.5±6.5 0.201
Fibrinogen (g/L) 3.3±1.4 3.3±1.4 0.870
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
NIHSS, National Institutes of Health Stroke Scale.
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Supplementary Table 2. Etiologic mechanisms of stroke in 129 patients 




Patent foramen ovale (with venous thrombosis) 7
Akinetic left ventricular segment 3
Hypokinetic left ventricular segment 3
Valvular heart disease (prosthetic valve replacement) 2
Cardiac thrombus 2
Atrial septal aneurysm 1
Status of inserted pacemaker (sick sinus syndrome) 1
Infective endocarditis 1
Large artery atherosclerosis 46
Small artery disease 10
Other determined etiologies 3
Two or more causes 19
Large artery atherosclerosis+cardioembolism 14
Atrial fibrillation 11
Atrial flutter 1
Prosthetic valve replacement 1
Spontaneous echo contrast 1
Large artery atherosclerosis+small artery disease 3
Cardioembolism+small artery disease 2
Atrial fibrillation 2
